clipped from blogs.wsj.com
The company said Monday that the 18-month, 1,684-patient study – the largest Alzheimer’s-treatment study to date – showed Flurizan failed to improve cognitive functioning or activities of daily living, and added that Myriad is abandoning further efforts to develop the drug. This leaves Elan and Wyeth’s bapineuzumab and Eli Lilly’s gamma secretase inhibitor as the two leading candidates among disease-modifying Alzheimer’s drugs in development. |
My name is Bob DeMarco, I am an Alzheimer's Caregiver. My mother Dorothy lived with Alzheimer's Disease. We lived our lives one day at a time. IAAAC is a companion site of the Alzheimer's Reading Room.
Flurizan’s Failure Leaves Key Alzheimer’s Theory Unresolved
Labels:
alzheimer's,
caregiver,
dementia
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment